^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thrombopoietin receptor agonist

    Related drugs:
    2d
    A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    2d
    TQZ3469-BE-01: Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State (clinicaltrials.gov)
    P=N/A, N=36, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Mar 2020 --> Mar 2023
    Trial initiation date
    |
    Promacta (eltrombopag)
    6d
    Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=248, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2/3 trial
    6d
    CT-PLATE: Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. (clinicaltrials.gov)
    P2, N=136, Not yet recruiting, Nantes University Hospital
    New P2 trial
    |
    Nplate (romiplostim)
    15d
    The Use of Eltrombopag Post HSCT in BMFD (clinicaltrials.gov)
    P2/3, N=118, Completed, The First Affiliated Hospital of Soochow University | Recruiting --> Completed | Trial completion date: Jul 2027 --> Oct 2025
    Trial completion • Trial completion date
    |
    Promacta (eltrombopag)
    16d
    Eltrombopag olamine induces apoptosis in human breast adenocarcinoma and hepatocellular carcinoma cells through modulation of multiple apoptotic pathways. (PubMed, Sci Rep)
    Interactions of Eltrombopag with EGFR, FAS, p53, and TNFα proteins were detected through molecular docking simulations. These findings highlight the potential of Eltrombopag olamine as a repurposed, multi-targeted therapeutic candidate for the treatment of breast and liver cancer.
    Journal • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAPK1 (Mitogen-activated protein kinase 1) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • ANXA5 (Annexin A5)
    |
    EGFR expression
    |
    Promacta (eltrombopag)
    16d
    Herombopag Treated T-DM1 Induced Platelet Reduction (clinicaltrials.gov)
    P2, N=56, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial
    |
    Kadcyla (ado-trastuzumab emtansine)
    18d
    Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation-Induced Premature Aging. (PubMed, Pharmacol Res Perspect)
    Although bone marrow cell recovery was incomplete, spleen cell counts were significantly restored (2-fold) by 50 μg/kg RP, and SA-β-gal activity, a marker of cellular senescence, was also significantly suppressed by approximately 15%. These findings suggest that RP may partially ameliorate radiation-induced premature aging, providing a basis for future research addressing health issues associated with aging and radiation exposure.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    Nplate (romiplostim)
    22d
    A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    cisplatin • gemcitabine
    27d
    Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study (clinicaltrials.gov)
    P2, N=72, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    1m
    The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery (clinicaltrials.gov)
    P3, N=101, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial primary completion date
    1m
    Coexistence of Immune Thrombocytopenic Purpura and Bernard-Soulier Syndrome: A Rare Pediatric Case Report. (PubMed, Int Med Case Rep J)
    She was managed with intravenous immunoglobulin (IVIG) and corticosteroids; Eltrombopag was discontinued due of leukemic risk...The purpose of this case report is to illustrate the diagnostic challenges and therapeutic considerations in children with coexisting acquired (ITP) and inherited (BSS) thrombocytopenias, particularly in the presence of a leukemogenic predisposition gene (ETV6). This case underscores the importance of comprehensive genetic evaluation in guiding individualized therapy and long-term surveillance.
    Journal
    |
    ETV6 (ETS Variant Transcription Factor 6)
    |
    Promacta (eltrombopag)